Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Checkpoint inhibitor doubled disease-free survival time after surgery.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Opdivo plus chemotherapy led to a significant improvement in overall survival.
However, a majority of these chronic immune-related side effects were mild.
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
Opdivo plus Cabometyx reduced the risk of death by 40%.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
A larger Phase II trial has been launched to evaluate the combination’s efficacy and safety.
Keytruda plus chemotherapy should be a new standard of care as first-line therapy in patients with esophageal cancer, say researchers.
The immunotherapy combo improved overall survival compared with chemotherapy.
Opdivo and Keytruda are potential alternatives to current first-line therapies.
Metastatic kidney cancer patients with greater microbial diversity had better outcomes with immunotherapy.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Margaret has never stopped living and enjoying her life despite her disease and the side effects of her medication.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.